Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Sees Significant Decline in Short Interest

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 123,600 shares, a decrease of 11.3% from the August 15th total of 139,300 shares. Based on an average daily trading volume, of 292,900 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BLPH. Brookline Capital Management cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 5th. StockNews.com began coverage on Bellerophon Therapeutics in a report on Monday, September 11th. They set a “hold” rating for the company. HC Wainwright dropped their price objective on Bellerophon Therapeutics from $30.00 to $2.00 in a report on Tuesday, June 6th. Finally, Laidlaw cut Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 5th.

Bellerophon Therapeutics Stock Performance

Shares of BLPH stock traded up $0.03 on Monday, reaching $0.44. The company had a trading volume of 19,850 shares, compared to its average volume of 1,032,604. The company has a 50-day moving average of $0.49 and a 200-day moving average of $4.13. Bellerophon Therapeutics has a 12 month low of $0.37 and a 12 month high of $12.58.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.42) EPS for the quarter.

Institutional Trading of Bellerophon Therapeutics

Large investors have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new stake in Bellerophon Therapeutics during the 1st quarter worth approximately $7,338,000. Geode Capital Management LLC increased its stake in Bellerophon Therapeutics by 49.0% during the 1st quarter. Geode Capital Management LLC now owns 95,656 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 31,460 shares in the last quarter. Renaissance Technologies LLC boosted its position in Bellerophon Therapeutics by 13.0% during the 2nd quarter. Renaissance Technologies LLC now owns 209,399 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 24,100 shares during the last quarter. State Street Corp boosted its position in Bellerophon Therapeutics by 41.3% during the 1st quarter. State Street Corp now owns 30,127 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 8,800 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Bellerophon Therapeutics during the 1st quarter worth approximately $107,000. 28.88% of the stock is owned by institutional investors.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.